Brian Guth
Overview
Explore the profile of Brian Guth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Markert M, Shen R, Trautmann T, Guth B
J Pharmacol Toxicol Methods
. 2011 Jun;
64(1):25-41.
PMID: 21635956
Introduction: The QT interval of the electrocardiogram (ECG) reflects the duration of ventricular depolarization and repolarization. A drug-induced prolongation of ventricular repolarization, and thereby QT prolongation, is recognized to be...
12.
Sarazan R, Mittelstadt S, Guth B, Koerner J, Zhang J, Pettit S
Int J Toxicol
. 2011 Apr;
30(3):272-86.
PMID: 21527643
There are several recent examples where clinically significant, safety-related, drug effects on hemodynamics or cardiac function were not apparent until large clinical trials were completed or the drugs entered the...
13.
Markert M, Stubhan M, Mayer K, Trautmann T, Klumpp A, Schuler-Metz A, et al.
J Pharmacol Toxicol Methods
. 2009 May;
60(1):79-87.
PMID: 19427912
Introduction: The objective of this study was to use a newly established cardiovascular model using freely moving minipigs to document the hemodynamic and electrocardiographic effects of known pharmacological agents. The...
14.
Eckhardt M, Hauel N, Himmelsbach F, Langkopf E, Nar H, Mark M, et al.
Bioorg Med Chem Lett
. 2008 May;
18(11):3158-62.
PMID: 18485703
Systematic variations of the xanthine scaffold in close analogs of development compound BI 1356 led to the class of 3,5-dihydro-imidazo[4,5-d]pyridazin-4-ones which provided, after substituent screening, a series of highly potent...
15.
Stubhan M, Markert M, Mayer K, Trautmann T, Klumpp A, Henke J, et al.
J Pharmacol Toxicol Methods
. 2008 Apr;
57(3):202-11.
PMID: 18434212
Introduction: The objective of this study was to evaluate the normal cardiovascular and ECG parameters in freely moving minipigs and to use these data as the basis of pharmacological drug...
16.
Eckhardt M, Langkopf E, Mark M, Tadayyon M, Thomas L, Nar H, et al.
J Med Chem
. 2007 Dec;
50(26):6450-3.
PMID: 18052023
A new chemical class of potent DPP-4 inhibitors structurally derived from the xanthine scaffold for the treatment of type 2 diabetes has been discovered and evaluated. Systematic structural variations have...
17.
Markert M, Klumpp A, Trautmann T, Mayer K, Stubhan M, Guth B
J Pharmacol Toxicol Methods
. 2007 Jun;
56(2):203-11.
PMID: 17583538
Introduction: The objective of this study was to define the normal LVdP/dt (an index of myocardial contractility)-heart rate relationship in telemetered conscious dogs, primates and mini-pigs in our laboratory and...
18.
Klumpp A, Trautmann T, Markert M, Guth B
J Pharmacol Toxicol Methods
. 2006 May;
54(2):141-9.
PMID: 16730461
Introduction: The objective of this study was to test the influence of housing conditions on hemodynamics during cardiovascular general pharmacological studies. Our goal was to optimize both the quality of...
19.
Pestel S, Martin H, Maier G, Guth B
J Pharmacol Toxicol Methods
. 2006 Mar;
54(2):200-14.
PMID: 16567111
Introduction: Solubility is often a limiting factor when testing new compounds in animal experiments. Various solubilizing agents may be used, but each have their own pharmacological effects. We investigated the...
20.
Muhs A, Lenter M, Seidler R, Zweigerdt R, Kirchengast M, Weser R, et al.
Gene Ther
. 2004 Oct;
11(23):1685-93.
PMID: 15470479
Local infusion of recombinant monocyte chemoattractant protein-1 (MCP-1) has been shown to enhance collateral artery formation in rabbit and pig hindlimb models. Owing to clinical disadvantages of protein infusion, a...